Hormone treatment enzalutamide will now be offered as an alternative combined treatment option for some adults with prostate cancer on the NHS in England.
A hormone therapy has been rejected for some adults with newly-diagnosed, advanced prostate cancer.
A hormone therapy has been approved for NHS use in Scotland for some people with newly diagnosed, advanced prostate cancer for the first time.
Combining a targeted drug with hormone therapy extended the lives of pre-menopausal women with advanced breast cancer in a clinical trial.
Using a test that measures gene activity could help to tailor treatment for some women with early stage breast cancer, new research suggests.
A new drug combo has been made available to some patients with advanced breast cancer on the NHS in England.
The prostate cancer drug abiraterone has been provisionally rejected as a first-line treatment on the NHS in England.
An experimental hormone therapy delays the spread of prostate cancer that has stopped responding to standard treatment, according to new clinical trial results.
Offering abiraterone (Zytiga) up-front with standard hormone treatment extends survival in men whose prostate cancer has spread.
Men with a high risk of prostate cancer recurrence could live longer if hormone treatment is given alongside radiotherapy after surgery.